Kalipso Chakidou1*, Ryan Li1, Anthony J. Culyer2, Amanda Glassman3, Karen J. Hofman4, Yot Teerawattananon5 1Institute of Global Health Innovation, Imperial College London, London, UK 2Department of Economics & Related Studies and Centre for Health Economics, University of York, York, UK 3Ce

Veronika J Wirtz*, Hans V Hogerzeil*, Andrew L Gray*, Maryam Bigdeli, Cornelis P de Joncheere, Margaret A Ewen, Martha Gyansa-Lutterodt, Sun Jing, Vera L Luiza, Regina M Mbindyo, Helene Möller, Corrina Moucheraud, Bernard Pécoul, Lembit Rägo, Arash Rashidian, Dennis Ross-Degnan, Peter N Stephens,

Songyot Pilasant1, Wantanee Kulpeng1, Pitsaphun Werayingyong1*, Nattha Tritasavit1, Inthira Yamabhai1, Yot Teerawattananon1, Sangay Wangmo2 and Sripen Tantivess1 Abstract Background: The Maternal and Child Health Voucher Scheme (MCHVS) was introduced in Myanmar to address the high rate of mat

Background Economic evaluation has been implemented to inform policy in many areas, including coverage decisions, technology pricing, and the development of clinical practice guidelines. However, there are barriers to evidence-based policy in low- and middle-income countries (LMICs) that include li

Abstract Introduction. Many countries have introduced pay-for-performance (P4P) models to encourage health providers and institutions to provide good quality of care. In 2013, the National Health Security Office of Thailand introduced P4P, based on the UK Quality and Outcomes Framework (QOF),

Objective: This study aims to compare the lifetime costs and health outcomes of both first-line and sequential combination treatments with standard treatment for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) (PAH-CHD) patients. Methods: A cost-utility analysis

Abstract Objectives This study aims to assess the value for money and budget impact of offering hemodialysis (HD) as a first-line treatment, or the HD-first policy, and the peritoneal dialysis (PD) first policy compared to a supportive care option in patients with end-stage renal disease (ESRD)

Abstract Background Policymakers in high-, low-, and middle-income countries alike face challenging choices about resource allocation in health. Economic evaluation can be useful in providing decision makers with the best evidence of the anticipated benefits of new investments, as well as their

As more countries provide free health care, pharmaceutical reimbursement lists are becoming a concern, especially in low- and middle-income countries. In 2007, Nepal decreed that health is a human right and began basic health coverage for a target group of the poor, destitute, elderly, and disabled.

Abstract Introduction Cancer has a high mortality rate and morbidity burden in Sri Lanka. This study estimated the economic cost of smoking and smokeless tobacco (ST) related to cancers in Sri Lanka in 2015. Methods Prevalence-based cost of illness is calculated according to the guidelines o